Covidien Receives FDA Approval for Nellcor

The U.S. Food and Drug Administration has granted Covidien 510(k) clearance to market the company’s Nellcor Bedside SpO2 Patient Monitoring System.

Advertisement

The Nellcor Bedside SpO2 system with OxiMax technology continuously monitors SpO2 and pulse rate for adult, pediatric and neonatal patients, giving clinicians instant access to comprehensive trending respiratory information. The system also includes technology to help differentiate between serious and minor events and reduce clinically insignificant oxygen desaturation alarms.

Learn more about Covidien.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.